ClinicalTrials.gg
SuspendedNCT03502499Updated Apr 11, 2022

Half-normal Saline in Idiopathic Left Ventricular Outflow Tract Arrhythmias Ablation

An interventional study of Half-normal saline and Normal saline in Ventricular Arrythmia, sponsored by Texas Cardiac Arrhythmia Research Foundation. Suspended at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-04-11.

Sponsored by Texas Cardiac Arrhythmia Research Foundation · Not applicable, Interventional, and Other

Why this study was suspended
slow enrollment
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study evaluates the use of half-normal saline as an irrigant for open-irrigated catheters during left ventricular outflow tract ventricular arrhythmias ablation. By increasing the efficacy of radiofrequency energy-mediated lesion formation, half-normal saline has the potential to reduce procedural times and improved acute and long-term outcomes.

02

Conditions studied

  • Ventricular Arrythmia
03

In context

Lead sponsor

Texas Cardiac Arrhythmia Research Foundation is the lead sponsor of 36 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female between 18 and 75 years of age at the time of enrollment
  • undergoing first-time radiofrequency ablation for left ventricular outflow tract ventricular arrhythmias
  • written obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study

Exclusion criteria

Exclusion criteria

  • ventricular arrhythmias originating from the right ventricular outflow tract according to the ventricular arrhythmia morphology (i.e., precordial R wave transition at V3 or later)
  • ventricular arrhythmias not originating from cardiac outflow tracts
  • baseline hyponatremia (serum sodium level \< 135 mEq/L)
  • pregnant, breastfeeding, or unwilling to practice during participation in the study
  • presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Half-normal saline

    Drug: Half-normal saline

  • Active comparator
    Normal saline

    Drug: Normal saline

Interventions

  • DrugHalf-normal saline

    Use of half-normal saline as an irrigant for open-irrigated ablation catheters

  • DrugNormal saline

    Use of normal saline as an irrigant for open-irrigated ablation catheters

06

What researchers measure

Primary outcomes

  1. total radiofrequency ablation time, and total procedure time

    Time frame: intraprocedural

  2. acute success

    elimination of the VAs, or \<10 morphologically similar PVCs during a 15-minute waiting period

    Time frame: intraprocedural

  3. long-term success

    elimination of the VAs, or a reduction of \>75% of the PVC burden associated with marked improved in symptoms

    Time frame: 1 year

Other outcomes

  1. procedure-related complications

    pericardial effusion due to cardiac perforation or pericarditis, transient ischemic attack/stroke, systemic embolism, coronary artery injury, death

    Time frame: periprocedural (at the time of the procedure and up to 1 month)

  2. hyponatremia

    serum sodium level \< 135 mEq/L

    Time frame: periprocedural (at the time of the procedure and up to 1 month)

07

Study locations

2 sites
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Texas Cardiac Arrhythmia Institute, St. David's Medical Center
    Austin, Texas 78705, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2018 (actual). Primary completion is estimated for Apr 2022, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2018
First posted
Apr 18, 2018
StartActual
May 16, 2018
Primary completionEst.
Apr 2022
CompletionEst.
Apr 2022
Last update
Apr 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03502499
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Responsible party
Andrea Natale (Executive Medical Director, Texas Cardiac Arrhythmia Research Foundation) — Principal investigator
First posted
Apr 18, 2018
Start date
May 16, 2018
Primary completion
Apr 2022 (estimated)
Completion
Apr 2022 (estimated)
Last update
Apr 11, 2022

Study contacts

Andrea Natale, MD
principal investigator · Texas Cardiac Arrhythmia Institute, St. David's Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion